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Background: Allergy to cow’s milk protein (CMP) may cause gastrointestinal (GI) symptoms in the absence of CMP
specific IgE. The immunological mechanisms involved in such disease are not fully understood. Therefore we
examined markers of gut mucosal inflammation and the immunoglobulin profiles in children with Gl symptoms
suspected of cow’s milk protein allergy (CMPA).
Patients and methods: We prospectively recruited infants and young children (n = 57; median age 8.7 months)
with gastrointestinal complaints suspected of CMPA. The diagnosis of CMPA was made using the double-blind,
placebo-controlled food challenge. Serum and stool samples were collected during CMP-free diet and after both
placebo and active challenges. We analyzed the stool samples for calprotectin, human β-defensin 2 and IgA. In
serum, we analyzed the levels of β-lactoglobulin and α-casein specific IgA, and IgG antibodies (total IgG and
subclasses IgG1 and IgG4). Control group included children with e.g. dermatological or pulmonary problems,
consuming normal diets.
Results: Fecal calprotectin levels were higher in the challenge positive group (n = 18) than in the negative (n = 37),
with respective geometric means 55 μg/g [95% confidence interval 38–81] and 29 [24–36] μg/g (p = 0.0039), during
cow’s milk free diet. There were no significant inter-group differences in the fecal β-defensin and IgA levels. The
CMP specific IgG and IgA were not elevated in patients with CMPA, but the levels of β-lactoglobulin-IgG4 (p = 0.0118)
and α-casein-IgG4 (p = 0.0044), and total α-casein-IgG (p = 0.0054) and -IgA (p = 0.0050) in all patient samples (regardless
of CMPA diagnosis) were significantly lower compared to the control group using dairy products.
Conclusions: Despite cow’s milk elimination in children intolerant to cow’s milk there might be ongoing low-grade
inflammation in the gut mucosa. CMP specific IgG or IgA should not be used to diagnose non-IgE CMPA. The observed
frequency of impaired CMP specific total IgA, IgG and IgG4 production in patients following cow’s milk free diet
warrants further studies.Introduction
Intolerance to cow’s milk protein may cause gastrointestinal
(GI) symptoms in infants. Such symptoms (in the absence
of atopic dermatitis) are usually non-IgE-mediated. In the
food-protein-induced enterocolitis syndrome (FPIES)
the suggested immunological (or allergic) pathophysi-
ology mainly involves T-cell-mediated reactions, as recently
reviewed [1]. Other immunological responses suggested in
the pathogenesis of the GI symptoms associating with cow’s* Correspondence: laura.merras-salmio@hus.fi
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article, unless otherwise stated.milk protein allergy (CMPA) include increased mono-
nuclear cell production of tumor necrosis factor-α (TNF-α)
[2], eosinophilic inflammation [3,4] as well as activated
submucosal mast cells [5]. Possible non-immunological
etiologies include 1) the direct effect of cow’s milk protein
on intestinal motility [6], 2) colonic bacterial dysbiosis
(possibly enhanced by cow’s milk formulas) [7,8], and 3)
effects caused by the non-protein parts of cow’s milk: car-
bohydrates [9] and fatty acids [10].
When CMPA is manifested by slowly developing gastro-
intestinal symptoms it should be separated from the more
common and easily-diagnosed IgE-mediated food allergy
[11]. In gastrointestinally manifested CMPA (GI-CMPA),Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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placebo-controlled food challenge (DBPCFC), and cow’s
milk specific IgE antibodies and skin prick tests (SPTs) are
usually negative. The prognosis for the non-IgE food al-
lergy is more favorable. Tolerance to cow’s milk in CMPA
patients has been shown to develop after age one, with
nearly 100% of the IgE-negative patients being tolerant by
age three, compared to 60% of the IgE positive [12]. The
levels of IgG4 subclass antibodies to CM specific allergens
were lower in the DBPCFC positive than in the negative
infants with eczema suspected of CMPA [13]. In GI-
CMPA, school-age children (4.0-10.8 years, n = 14) suf-
fering from non-IgE CMPA associated gastrointestinal
complaints had increased levels of β-lactoglobulin-IgG4
compared to controls [14], whereas in adults patients
(n = 19) with self-reported intolerance to CMP, the α-
casein and β-lactoglobulin-IgG4 levels were similar to
those in the controls [15]. CMP specific IgG4 data re-
garding infant patients with GI-CMPA is lacking.
Fecal calprotectin, a granulocyte protein binding calcium
that exerts antimicrobial effects, is an applicable surrogate
marker for gut mucosal inflammation [16], but it has not
been studied in GI-CMPA patients. Increased calprotectin
levels at six months of age have been associated with
lower risk of later atopic sensitization [17]. Human β-
defensins belong to a group of antimicrobial peptides
expressed in the epithelial cells as part of the innate im-
munity. Among their pleiotropic functions β-defensins
can activate antigen-presenting cells. Increased levels of
fecal β-defensin 2 in six-month-old children may associate
with later risk of atopic sensitization [18]. To better
understand the pathology of symptoms interpreted as GI-
CMPA, it is crucial to obtain more knowledge about what
happens in the gut mucosa in children with symptoms
suggestive of GI-CMPA.
The aims of the present study were 1) to examine
markers of inflammation derived from the gut mucosa,
and 2) to measure the total IgG, IgA, and IgG subclasses
(especially IgG4) to cow’s milk specific proteins, in chil-
dren suspected of having GI-CMPA.
Methods
We prospectively recruited children between 0 and 4 years
of age, who had been referred to the Pediatric Allergy Unit
(a tertiary level hospital for allergic and skin diseases) on
suspicion of gastrointestinally manifested CMPA during
the year 2010. All of the participants (n = 57) were follow-
ing a cow’s milk free diet and underwent DBPCFC for
cow’s milk and skin prick tests (SPTs) for cow’s milk and
hen’s egg. After a baseline evaluation we started the
DBPCFC for cow’s milk using the same hypoallergenic
formula as a placebo that the child had used during the
CM elimination period (an extensively hydrolyzed for-
mula, an amino acid –based formula or a soy formula).Parents kept a standard symptom diary, including items
on daily stool consistency (Bristol score) and frequency,
and possible infectious symptoms, one week before the
challenges and during the challenge period. The details of
our five-day DBPCFC protocol were recently published
[11]. We took serum and stool samples prior to the
DBPCFC, and during each provocation period (3–5 days
after the start of either the active or placebo provoca-
tion). The fecal samples were sent to laboratory in room
temperature and stored at −20°C.
The control group consisted of 22 children between
the ages of 0 and 4, who were recruited during the study
period when they visited the Pediatric Allergy Unit for
other reasons than food allergy, atopic eczema, or atopic
asthma, such as suspected drug allergies, and non-atopic
wheezing.
The methodology used for the SPTs has been described
in a previous study [11]. Reactions with a mean wheal
diameter of 3 mm or larger were considered positive. We
determined serum cow’s milk-specific IgE (Phadia Immu-
nocap, detection limit 0.35 kU/l) using the routine, com-
mercially available method.
Measurement of CM and ovalbumin specific antibodies
Serum antibodies of IgA, IgG, IgG1, and IgG4 isotypes
for cow’s milk β-lactoglobulin and α-casein and ovalbu-
min were measured using enzyme-linked immunosorb-
ent assays (ELISA) with the results reported as Arbitrary
Units (AU), based on previous reports for the antigen-
specific IgA and IgG [19], and for the antigen-specific
IgG4 and IgG1 [20]. The Arbitrary Units (AU) are de-
duced from the optical densities of the reference serum
curve with a high level of antibodies after subtracting
the blanks. The reference serum was a separate pool of
sera collected for IgA and IgG isotypes; its concentration
was assigned to 100 AU. The detection limits (expressed
as AU) were as follows: α-casein-specific IgA 0.26; IgG
0.70; IgG1 0.28; IgG4 0.28, β-lactoglobulin-specific IgA
0.3; IgG 0.028; IgG1 0.028; IgG4 0.028, and ovalbumin-
specific IgA 1.5; IgG 0.26; IgG1 1.3; IgG4 5.20.
Measurement of fecal β-defensin 2, fecal IgA, and fecal
calprotectin
Fecal calprotectin was analyzed immediately using PhiCal
Test (Calpro AS, Oslo, Norway; NovaTec Immunodiag-
nostica, Dietzenbach, GmBH, Germany). Prior to fecal β-
defensin 2 and Immunoglobulin A (F-IgA) analyses,
thawed samples were homogenized in phosphate-saline
buffer and centrifuged for 15 min at 10 000 g, +4°C, to
retrieve a supernatant for the measurements. We applied
enzyme linked immunosorbent assays (ELISA) accord-
ing to the manufacturers’ instructions for measuring
fecal levels of human β-defensin 2 (Immundiagnostik,
Bensheim, Germany; detection limit 0.077 ng/mL). Fecal
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method described before [21]. The detection limit for
F-IgA was 5 μg IgA/l.Statistical analyses
We analyzed the laboratory data for the three different
study groups (DBPCFC positive patients, DBPCFC negative
patients, and control patients) using the non-parametric
ANOVA (Kruskall-Wallis) test to compare three me-
dians. One-to-one comparisons were done using the non-
parametric Mann-Whitney’s test (if unpaired data) or in
the case of paired data, using the Wilcoxon matched-pairs
signed rank test. Spearman’s test was employed for deter-
mining the correlations. We report geometric means for
each measurement, with 95% confidence intervals for this
mean. Values below the detection limit (in the serum anti-
body samples only) were computed by dividing the detec-
tion limit by two. We conducted all of the analyses usingTable 1 Characteristics of pediatric patients with gastrointest
All patients Challenge ne
n = 57 n = 39
Age, months (median, range) 8.7 (2.4–40.8) 8.7 (2.5 –25.6)
Duration of CM free diet before
challenge, months (median, range)
2.5 (0.5–35) 2.4 (0.5–14)
CM specifig IgE > 0.35 kU/l 0 0
SPT wheal size ≥3 mm for cow’s milk 4 2
Symptoms associated with CMA suspicion
Loose stools, n (%) 18 (46%)
During CM challenge 1
Placebo challenge 10
Excessive crying, n (%) 30 (77%)
During CM challenge 2
Placebo challenge 15
Vomiting/reflux, n (%) 19 (49%)
During CM challenge 0
Placebo challenge 7
Constipation, n (%) 10 (26%)
During CM challenge 0
Placebo challenge 0
Skin eruptions, n(%) 10 (26%)
During CM challenge 2
Placebo challenge 2
CM Cow’s Milk.
SPT Skin Prick test.




*p-values below 0.05 are considered significant.
This table is modified from Merras-Salmio et al. [11].GraphPad Prism software (version 5.0 for Mac) and con-
sidered p-values below 0.05 as significant.
Ethics
This study was approved by the Helsinki University Hos-
pital Ethics Committee (No.317/13/03/03/2009). Both
legal guardians gave their written informed consent before
the child was enrolled in the study.
Results
The clinical characteristics of the patients suspected of
having CMPA based on gastrointestinal symptoms and
those of the control group are depicted in Table 1. The
majority of patients presented with excessive crying or
fussiness, vomiting or loose stools, with almost half of
them reporting three or more symptoms. The DBPCFC
ruled out cow’s milk protein intolerance for the majority:
only 18/57 (32%, median age 8.4 months[2.4-40.8]) of
the DBPCFC’s were deemed positive. At least oneinal symptoms suggestive of non-IgE cow’s milk allergy
gative Challenge positive p-value* Controls
(with no food allergies)
n = 18 n = 22
8.4 (2.4–40.8) NS 13.2 (4.8–30)


















Merras-Salmio et al. Clinical and Translational Allergy 2014, 4:8 Page 4 of 8
http://www.ctajournal.com/content/4/1/8associated symptom was loose stools for the majority
(14/18) of positive challenges, while the most common
(in 77%) symptom among the DBPCFC negative patients
(median age 8.7 months[2.5-25.6]) was excessive crying/
fussiness. A more detailed report on the DBPCFC results
can be found in a recently published article [11]. None
of the patients or controls had detectable levels of cow’s
milk specific IgE. Two patients in each study group had
a wheal diameter of 3 mm for the CM SPT; one of the
DBPCFC positive patients also had a positive SPT for
hen’s egg (4 mm). All of these SPT reactions were within
a low probability range for IgE-mediated allergic disease
[22]. None of these children showed signs of such at the
six-month follow-up.
Fecal calprotectin levels were higher in the DBPCFC
positive group than in the challenge negative group: the
respective geometric means being 55 μg/g [95% confi-
dence Interval: 38–81] and 29 μg/g [24–36] (p = 0.0039).
Table 2 and Figure 1 show the results of further subdiv-
ision into samples taken during cow’s milk free diet and
after the challenge with cow’s milk. The within-group
variation in calprotectin levels was high in both patient
groups, compared to controls with a slightly higher me-
dian age. Fecal calprotectin correlated weakly with fecal
IgA in the DBPCFC positive group (Spearman correl-
ation coefficient 0.4583, p = 0.0567) and in the control
group (Spearman correlation coefficient 0.5875, p =
0.0272), but not in the DBPCFC negative group. Fecal β-
defensin 2 and IgA showed high levels of within-group
variation and a trend towards higher median levels in
the DBPCFC positive, but the differences between the
groups were not significant (Table 2). Fecal occult blood
test positivity (in two DBPCFC patients pre-challenge
and in four DBPCFC negative patients either pre- or
post challenge) did not associate with the levels of fecal
inflammatory markers (data not shown).Table 2 Fecal calprotectin, IgA and β-defensin 2 levels in you
suggestive of non-IgE cow’s milk allergy
Cow’s milk free
Fecal calprotectin (μg/g) CMA positive (n = 18) 52 [33–86]*
CMA negative (n = 39) 28 [21–36]*
p-value *0.0203
Fecal IgA (g/l) CMA positive (n = 18) 0.54 [0.37–0.7
CMA negative (n = 39) 0.46 [0.35–0.6
p-value 0.6349
Fecal β-defensin2 (ng/ml) CMA positive (n = 18) 38.6 [19.6–75.
CMA negative (n = 39) 22.4 [14.5–34.
p-value 0.1976
Cow’s milk allergy was diagnosed with the double-blind, placebo-controlled food challen
*Mann–Whitney test p-values reported between the two patients groups. Values be
† Fecal samples taken 3–5 days after start of cow’s milk containing challenge formuThe α-casein-specific levels of IgG4 and total IgG and
IgA, in comparison to the controls were lower in the
study patients (Table 3). We found no significant differ-
ences between the DBPCFC positive patients and the
DBPCFC negative patients. The levels of β-lactoglobulin
IgG4 in the study patients were also independent of the
DBPCFC result, and lower than those for the control
group using cow’s milk normally (p = 0.0029, Table 3).
The levels for β-lactoglobulin total IgG and IgG1, and α-
casein IgG1 did not differ between the three groups.
Ovalbumin-specific IgA, IgG, IgG1 and IgG4 levels were
similarly low in all groups (Table 3). None of the pa-
tients had suspected or proven hen’s egg allergy either at
baseline or during follow-up.
Discussion
Gastrointestinally manifested (non-IgE) CMA is a diag-
nostically challenging disease. Despite our attempts, we
did not find laboratory measurements that could serve
as an additional tool for the diagnosis at the individual
level. However, the average fecal calprotectin levels of
the DBPCFC positive patients following a cow’s milk free
diet were higher than those of the challenge-negative pa-
tients and controls. There was no further increase in the
calprotectin levels after provocation with cow’s milk.
The difference between the groups was small, and most
values still remained within the normal range but this
finding certainly raises the need for future studies. The
levels of both β-lactoglobulin and α-casein specific IgG4;
and α-casein total IgG and IgA, were significantly low in
both patient groups on cow’s milk free diet compared to
the controls without diet restrictions.
In infancy, calprotectin levels are known to vary. The
median age of our patients was close to 9 months in
both the challenge negative and positive groups. Low
grade mucosal inflammation, as suggested by theng children (n = 57) with gastrointestinal symptoms
diet Cow’s milk challenge† p-value Controls (n = 22)
60 [30–122] 0.5995 25 [13–50]
33 [24–44] 0.4674
0.0737
9] 0.48 [0.36–0.62] 0.4509 0.33 [0.22–0.51]
1] 0.45 [0.36–0.55] 0.3138
0.8086
7] 47.50 [23.1–97.8] 0.1354 20.8 [8.6–50.0]
6] 31.12 [20.5–47.3] 0.1144
0.2520
ge. Values in table are geometric means [95% Confidence Interval of the mean].






















on CMP free diet
DBPCFC negative
 after CMP provocation
(3 data points are outside the axis limits)
* p=0.0203 p=0.0737
Figure 1 Fecal calprotectin in children (n = 57) with suspicion of gastrointestinally manifested cow’s milk allergy. The double-blind,
placebo-controlled food challenge (DBPCFC) was used to diagnose the cow’s milk allergy: n = 18 for DBPCFC positive patients and n = 39 for
DBPCFC negative patients. The graph shows Tukey’s whiskers with medians. (CMP = Cow’s Milk Protein).
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and endorse the development of allergies in susceptible
patients [23], but also contrary evidence exists [17]. The
gut microbiota composition (higher values for clostridia
and staphylococci colonization) affects the stool calprotec-
tin excretion in neonates [24]. In infants with colicky cry-
ing, fecal calprotectin levels tend to be higher than in the
non-crying controls [25], with aberrant colonic bacterial
colonization [26]. On the other hand, at the age of three
months, babies on CM formula had lower calprotectin
levels than those who were breast-fed [27]. Regarding the
here presented evidence suggesting low-grade gut mucosal
inflammation continuing during the cow’s milk free diet, it
is of interest that according to a registry study in Finland,
there is a distinct association between the diagnosis of gas-
trointestinally manifested CMPA in early childhood and
the later development of IBD in adolescence [28]. Unfor-
tunately, the high variation in the calprotectin levels in the
present study renders this test unfit for use in the diagnos-
tic process for GI-CMPA, but this finding certainly needs
to be further studied.
The low or undetectable levels of IgG and IgA anti-
bodies to bovine α-casein and β-lactoglobulin deserveattention. In infancy, although a relative immaturity exists
in producing antibodies IgG and IgA in total, especially
IgG4 production is low with the nadir at 4–6 months of
age and reaching adult levels only in adolescence [29].
Therefore the slightly different median ages in patients
and controls may partly explain this finding. However,
levels of IgG4 were only in the control group similar to
those previously published in asymptomatic infants (me-
dian age six months), using the same method [13]. Levels
of β-lactoglobulin-IgG4 in that study where lower in the
CMPA patients with mucocutaneous symptoms (combin-
ing IgE and non-IgE-mediated reactions). Another study
on older children with challenge-proven non-IgE GI-
CMPA reported levels of β-lactoglobulin-IgG4 to be
higher than in the controls [14]. In the present study, ov-
albumin IgG4 levels were similar between the three
groups, and in line with the previous work [13], indicating
unperturbed capability to age-appropriate production of
IgG4. Thus the low levels of CMP specific IgG4 (and α-
casein specific total IgG and IgA) we found likely reflect
the cow’s milk free diet in the patients, using whey hydrol-
ysate formulas or total CM elimination. The non-allergic
controls used CM normally. Higher or rising levels of
Table 3 Pre-challenge levels of serum α-casein, β-lactoglobulin and ovalbumin specific IgA, IgG (total) and IgG4 in
young children with gastrointestinal symptoms suggestive of non-IgE cow’s milk allergy
DBPCFC negative DBPCFC positive p-values* Controls
(with no diet restrictions)
p-values**
n = 39 n = 18 n = 22
α-casein
Total IgG 1.16 (0.80–1.70) 1.36 (0.64–2.88) 0.8410 4.16 (2.01–8.60) 0.0054*
IgG1 0.54 (0.30–1.0) 0.52 (0.25–1.11) 0.7300 0.84 (0.31–2.26) 0.7761
IgG4 0.07 (0.05–0.10) 0.09 (0.04–0.19) 0.6394 0.21 (0.11–0.37) 0.0024*
Total IgA 1.46 (1.00–2.13) 1.33 (0–71–2.50) 0.4969 4.14 (2.20–7.80) 0.0050*
β-lactoglobulin
Total IgG 0.43 (0.28–0.70) 0.27 (0.10–0.71) 0.3924 0.44 (0.27–0.69) 0.5770
IgG1 0.026 (0.009–0.07) 0.04 (0.01–0.19) 0.5463 0.05 (0.001–0.20) 0.6848
IgG4 0.004 (0.001–0.009) 0.005 (0.0001–0.03) 0.9362 0.06 (0.01–0.29) 0.0029*
Total IgA 0.35 (0.24–0.51) 0.35 (0.20–0.60) 0.9743 0.96 (0.50–1.86) 0.0100*
Ovalbumin
Total IgG 2.67 (1.24–5.75) 3.40 (0.95–12.14) 0.5857 3.27 (0.95–11.27) 0.8053
IgG1 0.58 (0.27–1.25) 0.95 (0.28–3.24) 0.4520 1.26 (0.40–4.00) 0.3756
IgG4 0.11 (0.05–0.23) 0.25 (0.07–0.92) 0.1652 0.21 (0.05–0.73) 0.3299
Total IgA 1.34 (0.97–1.86) 0.89 (0.69–1.1) 0.1147 1.82 (0.95–3.48) 0.1087
These levels are expressed as Arbitrary Units (AU). Cow’s milk allergy was diagnosed with the double-blind, placebo-controlled food challenge (DBPCFC). Reported
figures are geometric means (with 95% confidence interval of the mean).
*The Mann–Whitney test p-value between the two patient groups.
**p-values calculated by multiple comparison ANOVA (nonparametric Kruskall-Wallis test), comparing the two patient groups and the control group.
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ance to cow’s milk in IgE mediated CMPA [30,31]. It is
unclear whether a prolonged CM free diet in a non-
allergic infant could predispose to the development of
CMPA. Worsening of IgE-mediated food allergy after
elimination diets have been reported [32]. Our findings
do indicate that the CM free diet associates with de-
creased production of most CM specific immunoglobu-
lins. On the other hand, since higher levels of the CM
specific IgGs or IgA were found in asymptomatic con-
trols, these tests should not be used in diagnosing GI-
CMPA.
Fecal IgA levels taken during cow’s milk elimination diet
showed a trend towards higher values in the DBPCFC
positive patients. A previous study on 25 patients sus-
pected of non-IgE CMPA also failed to demonstrate a sig-
nificant difference in fecal secretory IgA levels between
the CMPA positive and negative [33]. A study pooling
both IgE and non-IgE-mediated CMPA did find signifi-
cantly higher fecal IgA levels in patients (pre-challenge) in
those with positive cow’s milk challenge than in the chal-
lenge negative [21]. As none of our patients had CMP spe-
cific IgE, the fecal IgA secretion may not be as relevant in
non-IgE CMPA.
This study has certain limitations. Though amongst
the largest published for gastrointestinally manifesting
non-IgE CMPA, the sample size was still relatively small,affecting in particular the DBPCFC positive group. To
address the association between calprotectin and gut
mucosal proinflammatory markers, larger studies on pa-
tients with a suspicion of gastrointestinally manifested,
non-IgE mediated CMPA are needed. Also, due to sam-
ple size, separating the DBPCFC positive patients based
on their symptoms or other clinical parameters was not
feasible. None of our patients presented with symptoms
suggestive of food-protein induced enterocolitis (immedi-
ate pallor, vomiting and subsequent diarrhea [34]), which
has indeed become a rarity in our clinical practice. The
stool samples that we collected in this study were not im-
mediately frozen, but instead were transported at room
temperature to laboratory within one to two days. This
proved to be feasible when measuring fecal calprotectin
[35], but the lengthy preservation of the samples at room
temperature may have had a minor effect on fecal IgA and
β-defensin.
The major strength of this study is that it is one of the
largest studies published so far that focuses on the
gastrointestinal manifestations of CMPA. The use of the
DBPCFC in the present study adds to the credibility of
our results. It is obvious from previous research that a
non-IgE mediated food intolerance/allergy has a distinct
pathophysiology compared to the IgE mediated aller-
gies. The results from studies focusing on IgE mediated
CMPA are probably not relevant in managing patients
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col we used was feasible in the daily clinical practice
and well received by the parents. In fact, the use of a
DBPCFC should be mandatory when diagnosing GI-
CMPA, due to the frequently observed placebo symp-
toms [11]. Even with the DBPCFC, the likelihood of
false positive diagnoses here is significant. We did not
use repeated testing to overcome this possibility, as
many GI-CMPA patients suffer from problematic feed-
ing, and prolonging the other dietary restrictions (as re-
quired by the food challenge protocol) further would
have been unethical.
In conclusion, we found evidence indicating low-grade
inflammation in gut mucosa as suggested by slightly ele-
vated fecal calprotectin levels in infants who tested positive
for GI-CMPA (presenting with diarrhea and vomiting)
during the cow’s milk challenge. The increase in calprotec-
tin was independent of cow’s milk elimination or provoca-
tion. This finding may indicate a novel pathophysiology
behind the symptoms associated with GI-CMPA, but fecal
calprotectin cannot be used in the diagnostic process due
to the high degree of variation in the levels. We also dis-
covered that the dietary elimination of cow’s milk protein
results in low levels of CM specific IgA, total IgG and
IgG4. Whether this associates with slower development of
tolerance to cow’s milk needs to be further studied. The
findings address the importance of accurate diagnostics of
GI-CMPA and emphasize that the need of strict cow’s
milk elimination should be thoroughly considered.
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